| Project/Area Number |
26870390
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
Digestive surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Kuroda Shinji 岡山大学, 医学部, 客員研究員 (60633758)
|
|---|
| Research Collaborator |
KUBOTA Tetsushi 岡山大学大学院医歯薬学総合研究科, 消化器外科学, 大学院生
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 金ナノ粒子 / トラスツズマブ / HER2 / 胃癌 / トラスツズマブ抵抗性 / トラスツヅマブ |
|---|
| Outline of Final Research Achievements |
Trastuzumab (Tmab)-conjugated gold nanoparticles (Tmab-AuNP) showed strong cytotoxic effect on a Tmab-resistant HER2-positive gastric cancer cell line while Tmab did not. On a HER2-negative gastric cancer cell line, Tmab-AuNP showed strong cytotoxic effect after HER2 extra-cellular domain was over-expressed on the cell surface. These specific cytotoxic activity of Tmab-AuNP was produced through increase of oxidative stress and autophagy induced after intracellular uptake of Tmab-AuNP. These findings demonstrated that Tmab-AuNP could be a novel intriguing therapeutic agent for Tmab-resistant cancers.
|
